After all, obesity help can come in a pill, according to a new study involving a diabetes treatment that led to remarkable weight loss for the average participant.
“A medical treatment for obesity that leads to a 10% weight loss in the majority and 20% in more than a third of the participants. This is the beginning of a new era, ”said Rachel Batterham, one of the researchers involved in the study and a professor of obesity, diabetes and endocrinology and director of the UCL Center for Obesity Research and the Center for Weight Management at UCL. the UCLH, in Twitter
A total of 1,961 adults from North America, South America, Asia and Europe participated in the 68-week trial during 2018 that involved the drug semaglutide, which is an antidiabetic drug used to treat type 2 diabetes, according to the study. which was published in The New England Journal of Medicine on Wednesday,
The individuals received a weekly injection of semaglutide under the skin or a placebo, along with counseling sessions to adhere to a low-calorie diet and increase exercise. Semaglutide is sold under the names Ozempic and Rybelsus by the Danish pharmaceutical company Novo Nordisk NVO,
“Participants who received semaglutide were more likely to lose 5% or more, 10% or more, 15% or more and 20% or more of their baseline body weight at week 68 than those who received placebo,” he said. the study.
Trial participants were 18 years of age or older, with one or more previous dietary attempts to lose weight and with a body mass index (BMI) of 30 or more, or a BMI of 27 with one or more weight-related conditions, treated or not treated. A normal BMI tends to fall in the range of 18.5 to 24.9.
“Our trial showed that among overweight or obese adults (without diabetes), subcutaneous semaglutide once weekly plus a lifestyle intervention was associated with a clinically relevant, sustained, and substantial mean weight loss of 14, 9%, with 86% of participants achieving at least 5% weight loss, ”the study researchers said.
Novo Nordisk has submitted semaglutide as a weight control treatment for regulatory approval from the Food and Drug Administration and the European Medicines Agency.